Information Letter on CAELYX®: As of Monday 29 April 2013, supply with the medicinal product will return to normal
2013.04.23
Active substance: pegylated liposomal doxorubicin
Janssen-Cilag is sending out information that the supply with CAELYX® 2 mg/ml concentrate for solution for infusion is returning to regular availability and that the "CAELYX® Managed Access Programme" is being terminated.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN